HK Stock Market Move | Lithium carbonate futures once broke through 170,000 mark. Ganfeng Lithium Group (01772) and Tianqi Lithium Corporation (09696) both rose nearly 4%.
Lithium stocks rose again. As of the time of publication, Tianqi Lithium (09696) rose by 3.81% to 57.15 Hong Kong dollars, and Ganfeng Lithium (01772) rose by 3.72% to 61.35 Hong Kong dollars.
Lithium stocks rise again. As of press time, Tianqi Lithium Corporation (09696) rose by 3.81% to HKD 57.15, and Ganfeng Lithium Group (01772) rose by 3.72% to HKD 61.35.
On the news front, on January 13th, the main contract of lithium carbonate futures on the Guangzhou Futures Exchange once broke through the 170,000 yuan per ton mark, reaching a new high since October 2023. In addition, in terms of spot prices, according to the latest prices from the Shanghai Nonferrous Metals Network, on January 12th, the price of lithium carbonate (99.5% battery grade/domestic) rose by 12,080 yuan to 152,100 yuan per ton, hitting a new high in over 2 years, with consecutive rises for 7 days.
The Ministry of Finance and the State Administration of Taxation recently issued a notice on adjusting the export tax rebate policy for photovoltaic and other products. From April 1, 2026 to December 31, 2026, the export tax rebate rate for battery products will be reduced from 9% to 6%; starting from January 1, 2027, the export tax rebate for battery products will be canceled. Guosen's research report believes that due to a certain policy cushion period, there may be some overseas customers with a certain demand for rushed exports in the short term, and the industry chain may show a significant off-season not being dull.
Related Articles
.png)
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.
.png)
HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


